
New 2-year data show IMAAVY sustains disease control and reduces steroid use in adolescents with generalized myasthenia gravis.
Johnson & Johnson announced new two-year data from a Phase 2/3 study showing that IMAAVY (nipocalimab) provides sustained disease control, improved muscle strength, and reduced corticosteroid use in adolescents with generalized myasthenia gravis (gMG...





